Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs. bias in outcome measures in moderate and severe disease-Reference-Cited by-同舟云学术

Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs. bias in outcome measures in moderate and severe disease

Published:2019-08 Issue:8 Volume:33 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:J Eur Acad Dermatol Venereol

Author:

Frew J.W.¹^ORCID

Affiliation:

1. Laboratory of Investigative Dermatology The Rockefeller University New York NY USA

Funder

National Center for Advancing Translational Sciences

National Institutes of Health

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.15572

Reference10 articles.

1. Guselkumab in the treatment of severe hidradenitis suppurativa;Kovacs M;J Eur Acad Dermatol Venereol,2018

2. ClinicalTirals.gov [Internet] Bethesda MD: National Library of Medicine (US)2018Nov 29. Identifier: NCT03628924. A Study to Evaluate the Efficacy Safety and Tolerability of Guselkumab for the Treatment of Participants with Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA). Available from:https://www.clinicaltrials.gov/ct2/show/NCT03628924

3. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

4. Development and validation of the International Hidradenitis Suppurativa Severity Score System ( IHS 4), a novel dynamic scoring system to assess HS severity

5. Low and high body mass index in hidradenitis suppurativa patients-different subtypes?

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing severity, treatment response, and phenotype in HS;Dermatological Reviews;2022-01-25

2. Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review;Journal of Cutaneous Medicine and Surgery;2021-08-08

3. New perspectives on the treatment of hidradenitis suppurativa;Therapeutic Advances in Chronic Disease;2021-01

4. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice;Dermatologic Therapy;2020-09-15

5. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data;Journal of the American Academy of Dermatology;2020-05